BIOTHERYX

Biotheryx, Inc.

@biotheryx_inc.

San Diego, California
http://biotheryx.com
Biotechnology Research

Overview

About Biotheryx, Inc.

Biotheryx is a clinical-stage biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders, including bifunctional degraders and molecular glues. Our focus is on deploying the differentiated potential of degraders towards validated targets in cancer and inflammatory disease. Members of our founding and scientific teams previously developed the IMiDs, the first U.S. Food and Drug Administration (FDA) approved modulators of Cereblon, the most widely validated E3 ligase involved in protein degradation, and we have applied our expertise in Cereblon binding to build our proprietary PRODEGY platform. Biotheryx’s clinical program, BTX-9341, a bifunctional degrader of CDK4 and CDK6, began a Phase 1 clinical trial in the third quarter of 2024. Biotheryx’s pipeline also includes BTX-10908, a first-in-class degrader of SOS1 for pan-KRAS mutant cancers and PDE4 degraders for inflammatory diseases. For more information, please visit biotheryx.com.

Headquarters

San Diego, California

Website

http://biotheryx.com

Company Size

11-50 employees

Industry

Biotechnology Research

Company Type

Privately Held

Founded

2025

Specialties

Biotech, Targeted Protein Degredation, Cancer, Small Molecules , and Inflammatory Disorders

Posts